Top Markets
#1 Black Phoenix Black Phoenix +21,324.94%
#2 Nesa Nesa +680.44%
#3 Ontology Gas Ontology Gas +77.37%
#4 Kinesis Silver Kinesis Silver +53.96%
#5 Biconomy Biconomy +30.85%
#6 QuantixAI QuantixAI +23.11%
#7 EXOD EXOD +22.78%
#8 SAFEcoin SAFEcoin +19.07%
#9 BNB Attestation Service BNB Attestation Service +18.39%
#10 Magma Finance Magma Finance +17.20%
Coin of the day
Black Phoenix Black Phoenix
Ustawienia
Język
POLSKI
Waluta
USD
Motyw
Camurus AB Camurus AB

Camurus AB

CAMX
Pozycja w akcjach #4179
Camurus AB (publ), a biopharmaceutical company, develops and commercializes... Camurus AB (publ), a biopharmaceutical company, develops and commercializes medicines for severe and chronic diseases in Europe, Africa, the Middle East, North America, and Asia. The company offers Buvidal, a buprenorphine injection for the treatment of opioid dependence and chronic pain; and Brixadi to treat opioid use disorder. It also provides CAM2038 for the treatment of chronic pain; CAM2029, which completed phase III clinical trials for the treatment of acromegaly, and phase III clinical trials to treat gastroenteropancreatic neuroendocrine tumors, as well as in phase II clinical trial to treat polycystic liver diseases; and CAM2043 that is in phase I clinical trial for the treatment of pulmonary arterial hypertension, as well as in Phase II clinical trial to treat Raynaud’s phenomenon. In addition, the company is developing CAM2032, which is in phase II clinical trials for the treatment of prostate cancer; CAM4072 that is in phase III clinical trials for the treatment of genetic obesity disorders; CAM2056 that is in phase I clinical trials for the treatment of metabolic diseases; CAM4071, which is in phase I clinical trials for the treatment of endocrine disorder; and CAM2047 that is in phase 1 clinical trial for the treatment of chemotherapy-induced nausea and vomiting. It has strategic partnerships with Braeburn Pharmaceuticals to develop CAM2038 for the treatment of opioid use disorder; Rhythm Pharmaceuticals Inc. to develop CAM4072 for the treatment of a range of rare genetic disorders of obesity; and Gubra A/S to develop long-acting therapeutic option for the treatment of hypoparathyroidism; as well as NewBridge Pharmaceuticals. Camurus AB (publ) was founded in 1991 and is headquartered in Lund, Sweden.
Cena akcji
$67.97
Kapitalizacja rynkowa
$4.04B
Zmiana (1 dzień)
-1.06%
Zmiana (1 rok)
-7.50%
Kraj
SE
Handel Camurus AB (CAMX)

Kategoria

Healthcare
Historia dywidend dla Camurus AB (CAMX)
Camurus AB (symbol giełdowy: CAMX) wypłaciła łącznie 0 dywidend.
Suma wszystkich dywidend (skorygowana o podziały akcji): 0.00
Wskaźnik dywidendy (TTM): 0
Wypłaty dywidend dla Camurus AB (CAMX) od 2026 do 2026
Roczne wypłaty dywidend
Rok Dywidenda (skorygowana o podziały akcji) Zmień
Za mało danych dla podanych dat.
Lista wszystkich wypłat dywidend
Rok Dywidenda Zmień
Za mało danych dla podanych dat.
Wypłaty dywidend firm podobnych lub konkurencyjnych
Firma Liczba wypłat dywidend Kraj
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
0.00%
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
0.00%
NL
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
0.00%
US
CSL Limited CSL Limited
CSL Limited
CSL.AX
64.00%
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
0.00%
CH